THAR stock icon



Market Cap: 2.81M


About: Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Employees: 3

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 0

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

60% more funds holding

Funds holding: 5 [Q4 2023] → 8 (+3) [Q1 2024]

4.82% less ownership

Funds ownership: 5.38% [Q4 2023] → 0.56% (-4.82%) [Q1 2024]

59% less capital invested

Capital invested by funds: $68.8K [Q4 2023] → $28.3K (-$40.6K) [Q1 2024]

Research analyst outlook

We haven’t received any recent analyst ratings for THAR.

Financial journalist opinion